The Spanish Hematic Derivatives Group, consisting of 26 biobanks, was established in 2011. We describe here the viability results of our publically available standard operating procedure to freeze and thaw peripheral blood mononuclear cells (PBMCs). Our protocol maximizes PBMC viability while avoiding where possible interbiobank and intrabiobank assay variability.
Get full access to this article
View all access options for this article.
References
1.
CostantiniA, ManciniS, GiuliodoroS, et al.Effects of cryopreservation on lymphocyte immunophenotype and function. J Immunol Methods, 2003; 278:145–155.
2.
KreherCR, DittrichMT, GuerkovR, BoehmBO, Tary-LehmannM. CD4+ and CD8+ cells in cryopreserved human PBMC maintain full functionality in cytokine ELISPOT assays. J Immunol Methods, 2003; 278:79–93.
3.
WeinbergA, ZhangL, BrownD, et al.Viability and functional activity of cryopreserved mononuclear cells. Clin Diagn Lab Immunol, 2000; 7:714–716.
4.
BetenskyRA, ConnickE, DeversJ, et al.Shipment impairs lymphocyte proliferative responses to microbial antigens. Clin Diagn Lab Immunol, 2000; 7:759–763.
5.
WeinbergA, BetenskyRA, ZhangL, RayG. Effect of shipment, storage, anticoagulant, and cell separation on lymphocyte proliferation assays for human immunodeficiency virus-infected patients. Clin Diagn Lab Immunol, 1998; 5:804–807.
6.
ReimannKA, ChernoffM, WilkeningCL, NickersonCE, LandayAL. Preservation of lymphocyte immunophenotype and proliferative responses in cryopreserved peripheral blood mononuclear cells from human immunodeficiency virus type 1-infected donors: Implications for multicenter clinical trials. The ACTG Immunology Advanced Technology Laboratories. Clin Diagn Lab Immunol, 2000; 7:352–359.
7.
MaeckerHT, MoonJ, BhatiaS, et al.Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOT. BMC Immunol, 2005; 6:1–14, 17.
8.
DisisML, dela RosaC, GoodellV, et al.Maximizing the retention of antigen specific lymphocyte function after cryopreservation. J Immunol Methods, 2006; 308:13–18.
9.
RuitenbergJJ, MulderCB, MainoVC, LandayAL, GhanekarSA. VACUTAINER CPT and Ficoll density gradient separation perform equivalently in maintaining the quality and function of PBMC from HIV seropositive blood samples. BMC Immunol, 2006; 7:1–8, 11.
10.
RamosTV, MathewAJ, ThompsonML, EhrhardtRO. Standardized cryopreservation of human primary cells. Curr Protoc Cell Biol, 2014; 64:A.3I.1–A.3I.8.
11.
BestA, HidalgoG, MitchellK, YannelliJR. Issues concerning the large scale cryopreservation of peripheral blood mononuclear cells (PBMC) for immunotherapy trials. Cryobiology, 2007; 54:294–297.
12.
AzizN, MargolickJB, DetelsR, et al.Value of a quality assessment program in optimizing cryopreservation of peripheral blood mononuclear cells in a multicenter study. Clin Vaccine Immunol, 2013; 20:590–595.
13.
LucianoAM, ChigioniS, LoddeV, FranciosiF, LuvoniGC, ModinaSC. Effect of different cryopreservation protocols on cytoskeleton and gap junction mediated communication integrity in feline germinal vesicle stage oocytes. Cryobiology, 2009; 59:90–95.
14.
GermannA, SchulzJC, Kemp-KamkeB, ZimmermannH, von BriesenH. Standardized serum-free cryomedia maintain peripheral blood mononuclear cell viability, recovery, and antigen-specific T-cell response compared to fetal calf serum-based medium. Biopreserv Biobank, 2011; 9:229–236.
15.
KenmochiT, AsanoT, MaruyamaM, et al.Cryopreservation of human pancreatic islets from non-heart-beating donors using hydroxyethyl starch and dimethyl sulfoxide as cryoprotectants. Cell Transplant, 2008; 17:61–67.
16.
GermannA, OhYJ, SchmidtT, SchonU, ZimmermannH, von BriesenH. Temperature fluctuations during deep temperature cryopreservation reduce PBMC recovery, viability and T-cell function. Cryobiology, 2013; 67:193–200.
17.
FowkeKR, BehnkeJ, HansonC, SheaK, CosentinoLM. Apoptosis: A method for evaluating the cryopreservation of whole blood and peripheral blood mononuclear cells. J Immunol Methods, 2000; 244:139–144.
18.
OwenRE, SinclairE, EmuB, et al.Loss of T cell responses following long-term cryopreservation. J Immunol Methods, 2007; 326:93–115.
19.
SchulzJC, GermannA, Kemp-KamkeB, MazzottaA, von BriesenH, ZimmermannH. Towards a xeno-free and fully chemically defined cryopreservation medium for maintaining viability, recovery, and antigen-specific functionality of PBMC during long-term storage. J Immunol Methods, 2012; 382:24–31.
20.
WeinbergA, SongLY, WilkeningCL, et al.Optimization of storage and shipment of cryopreserved peripheral blood mononuclear cells from HIV-infected and uninfected individuals for ELISPOT assays. J Immunol Methods, 2010; 363:42–50.
21.
KofanovaOA, DavisK, GlazerB, De SouzaY, KesslerJ, BetsouF. Viable mononuclear cell stability study for implementation in a proficiency testing program: Impact of shipment conditions. Biopreserv Biobank, 2014; 12:206–216.
22.
OlemukanRE, EllerLA, OumaBJ, et al.Quality monitoring of HIV-1-infected and uninfected peripheral blood mononuclear cell samples in a resource-limited setting. Clin Vaccine Immunol, 2010; 17:910–918.
23.
RiccioEK, NevesI, BanicDM, et al.Cryopreservation of peripheral blood mononuclear cells does not significantly affect the levels of spontaneous apoptosis after 24-h culture. Cryobiology, 2002; 45:127–134.
24.
BlancoJR, JarrinI, MartinezA, et al.Shorter telomere length predicts poorer immunological recovery in virologically suppressed HIV-1-infected patients treated with combined antiretroviral therapy. J Acquir Immune Defic Syndr, 2015; 68:21–29.
25.
Vacas-CordobaE, GalanM, de la MataFJ, GomezR, PionM, Munoz-FernandezMA. Enhanced activity of carbosilane dendrimers against HIV when combined with reverse transcriptase inhibitor drugs: Searching for more potent microbicides. Int J Nanomedicine, 2014; 9:3591–3600.
26.
CasadoC, PernasM, SandonisV, et al.Identification of a cluster of HIV-1 controllers infected with low replicating viruses. PLoS One, 2013; 8:1–9, e77663.
27.
SainzT, Serrano-VillarS, DiazL, et al.The CD4/CD8 ratio as a marker T cell activation, senescence and activation/exhaustion in treated HIV-infected children and young adults. AIDS, 2013; 27:1513–1516.
28.
BunupuradahT, DuongT, CompagnucciA, et al.Outcomes after reinitiating antiretroviral therapy in children randomized to planned treatment interruptions. AIDS, 2013; 27:579–589.
29.
VallejoA, GutierrezC, Hernandez-NovoaB, et al.The effect of intensification with raltegravir on the HIV-1 reservoir of latently infected memory CD4 T cells in suppressed patients. AIDS, 2012; 26:1885–1894.
30.
GarciaF, Bernaldo de QuirosJC, GomezCE, et al.Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02). Vaccine, 2011; 29:8309–8316.
31.
MabileL, DalgleishR, ThorissonGA, et al.Quantifying the use of bioresources for promoting their sharing in scientific research. Gigascience, 2013; 2:1–8.
32.
BallanaE, Ruiz-de AndresA, MotheB, et al.Differential prevalence of the HLA-C—35 CC genotype among viremic long term non-progressor and elite controller HIV+ individuals. Immunobiology, 2012; 217:889–894.
33.
Martinez-BonetM, PuertasMC, FortunyC, et al.Establishment and replenishment of the viral reservoir in perinatally HIV-1-infected children initiating very early antiretroviral therapy. Clin Infect Dis, 2015; 61:1169–1178.
34.
KleinN, PalmaP, LuzuriagaK, et al.Early antiretroviral therapy in children perinatally infected with HIV: A unique opportunity to implement immunotherapeutic approaches to prolong viral remission. Lancet Infect Dis, 2015; 15:1108–1114.
